<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892450</url>
  </required_header>
  <id_info>
    <org_study_id>01143</org_study_id>
    <nct_id>NCT00892450</nct_id>
  </id_info>
  <brief_title>Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease</brief_title>
  <official_title>Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate the cognitive (thinking, memory,&#xD;
      knowledge, intelligence) side effects of two medications commonly used to treat overactive&#xD;
      bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the&#xD;
      Philadelphia PADRECC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a double-blinded cross-over clinical trial design to assess the prevalence&#xD;
      of cognitive effects, the efficacy, and the effect on quality of life (QOL) of two&#xD;
      anticholinergic medications commonly used in the treatment of overactive bladder (OAB):&#xD;
      oxybutynin and darifenacin. This will be done by use of a well-established and validated&#xD;
      computer-based cognitive battery. Secondary endpoints will assess efficacy of anticholinergic&#xD;
      therapy on symptoms of OAB via QOL questionnaire and participant urinary diaries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare cognitive side effects</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crossover design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin and darifenacin</intervention_name>
    <description>Participants with overactive bladder will take each medication for 4 weeks.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic PD (ICD9=332.0)&#xD;
&#xD;
          -  MMSE 24, able to give informed consent and complete questionnaires and voiding&#xD;
             diaries.&#xD;
&#xD;
          -  Urological work-up within 3 months of enrollment to:&#xD;
&#xD;
               -  Rule out treatable causes of urinary symptoms&#xD;
&#xD;
                    -  Urinalysis (UA)&#xD;
&#xD;
                    -  Post-void residual ultrasound (PVR)&#xD;
&#xD;
                    -  Urinary cytology&#xD;
&#xD;
               -  Documented symptoms OAB on screening 3-day voiding diary:&#xD;
&#xD;
                    -  Average of 1 urgency episode / 24 hours, and&#xD;
&#xD;
                    -  Average of 8 micturitions / 24 hours&#xD;
&#xD;
                    -  Subjective complaints of symptoms for 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to anticholinergics or antispasmodics within the last 4 weeks (among them:&#xD;
             atropine, tolterodine, benztropine, trihexyphenidyl, dicyclomine, hyoscyamine, and&#xD;
             scopolamine)&#xD;
&#xD;
          -  Exposure to drugs with known effects on cognition (i.e. opioids, benzodiazepines or&#xD;
             sedating antihistamines) within the last week&#xD;
&#xD;
          -  Exposure to drugs contraindicated or cautioned in use with the 2 study medications&#xD;
             (drugs that also use the cytochrome P450 enzyme, primarily CYP3A4). These include:&#xD;
             ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, ritonavir,&#xD;
             nelfinavir, nefazodone, flecainide, thioridazine and tricyclic antidepressants.&#xD;
&#xD;
          -  Nonpharmacological treatment of OAB within the last 4 weeks (for example: biofeedback,&#xD;
             physical therapy, acupuncture)&#xD;
&#xD;
          -  Uncontrolled narrow angle glaucoma&#xD;
&#xD;
          -  History of gastric or urinary retention / dysmotility (ulcerative colitis, myasthenia&#xD;
             gravis and severe constipation)&#xD;
&#xD;
          -  History of hepatic or renal impairment&#xD;
&#xD;
          -  History of severe gastro-esophageal reflux disease and/or use of bisphosphonates,&#xD;
             patients at risk for esophagitis&#xD;
&#xD;
          -  Previous exposure to anticholinergic for OAB symptoms that resulted in side effects&#xD;
             that caused cessation of the medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayne R Wilkinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive bladder symptoms</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>darifenacin</keyword>
  <keyword>oxybutynin</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

